廣告
香港股市 將收市，收市時間：44 分鐘

  • 恒指

    17,874.54
    -153.74 (-0.85%)
     

  • 國指

    6,410.22
    -60.64 (-0.94%)
     

  • 上證綜指

    2,949.93
    -7.63 (-0.26%)
     

  • 滬深300

    3,431.06
    -14.75 (-0.43%)
     

  • 美元

    7.8104
    +0.0011 (+0.01%)
     

  • 人民幣

    0.9301
    +0.0001 (+0.01%)
     

  • 道指

    39,308.00
    -23.90 (-0.06%)
     

  • 標普 500

    5,537.02
    +28.01 (+0.51%)
     

  • 納指

    18,188.30
    +159.54 (+0.88%)
     

  • 日圓

    0.0483
    +0.0002 (+0.31%)
     

  • 歐元

    8.4515
    +0.0097 (+0.11%)
     

  • 英鎊

    9.9690
    +0.0070 (+0.07%)
     

  • 紐約期油

    84.00
    +0.12 (+0.14%)
     

  • 金價

    2,372.20
    +2.80 (+0.12%)
     

  • Bitcoin

    54,309.21
    -4,267.06 (-7.28%)
     

  • CMC Crypto 200

    1,123.95
    -84.74 (-7.01%)
     

Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant

Vandana Singh
·2 分鐘文章
Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant
Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant

French drugmaker Sanofi is poised to commit between 1.3 billion euros and 1.5 billion euros ($1.4 billion – $1.6 billion) to enhancing its insulin production site in Frankfurt, Germany.

The site in Frankfurt’s Hoechst district is known for producing the company’s insulin brand, Lantus.

Also Read: Hawaii Court Rules Against Bristol Myers, Sanofi In Blood Clot Drug Case, Increases Liability To $916M.

This move comes after initial plans to shift Lantus production to France were reconsidered.

The decision to invest in the Frankfurt site represents a significant victory for Germany’s healthcare sector.

Germany’s ruling coalition has been actively working to attract healthcare investments. In February, Daiichi Sankyo announced plans to spend around 1 billion euros to advance its precision cancer drug work near Munich.

廣告

Eli Lilly (NYSE:LLY) also committed 2.3 billion euros last November to produce obesity and diabetes medications in Germany.

Sanofi’s investment is expected to bolster its production capabilities and reinforce its commitment to maintaining a strong manufacturing presence in Germany.

Reuters noted that the upgrade will likely enhance Lantus’s supply chain stability and support Sanofi’s long-term strategic goals.

In May, Sanofi announced an investment of more than €1 billion to create new bioproduction capacity at its French sites in Vitry-sur-Seine (Val de Marne), Le Trait (Seine-Maritime), and Lyon Gerland (Rhône).

Read Next:

Price Action: At the last check on Monday, SNY shares were up 1.96% at $49.47.

Image by HJBC via Shutterstock

"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!

Get the latest stock analysis from Benzinga?

This article Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.